Clinical trials: Hematological Patients
Acute Myeloid Leukemia, Multiple Myeloma
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03106428
- Testing
- MEDI7247
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
Infectious Diseases, Hematological Malignancies
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies
- Trial name
- NCT04657965
- Testing
- LMP1 CAR T-cells
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Zhejiang University
AML, Adult Recurrent, MDS
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk…
- Trial name
- NCT05829226
- Testing
- LYT-200, Venetoclax, Azacitidine
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- PureTech
Haematological Malignancy
Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI
Total body irradiation (TBI) is a standard part of the conditioning regimen for bone marrow transplantation (BMT). Several randomized trials have shown superior outcomes using TBI compared with non TBI-containing regimens.
- Trial name
- NCT03262220
- Testing
- Volumetric Arc Therapy (VMAT)
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Thomas Zilli
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hematologic Malignancy, Neutropenia
Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers).
- Conditions
- Hematologic Malignancy, Neutropenia, Bone Pain
- Trial name
- NCT07300735
- Testing
- Loratadine, Diosmin-Hesperidin, Loratadine + Diosmin-Hesperidin
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Alexandria University
Solid Tumors
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
- Trial name
- NCT00687934
- Testing
- STA-9090
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Synta Pharmaceuticals Corp.
Chronic Lymphocytic Leukemia (CLL)
Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients
the goal of this study is To describe the clinical, hematologic, and cytogenetic characteristics of CLL cases. The main questions it aims to answer are: 1.
- Trial name
- NCT07162532
- Testing
- 1 Complete blood picture (CBC) with blood film, lymphocytic count 2 and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests ,deletion 17p,IGVH mutation,ESR
- Volunteers
- 45 people
- Sponsor
- Assiut University
Relapsed/Refractory Hematological Malignancies
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in…
- Trial name
- NCT07294300
- Testing
- QLS2313
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Leukemia, Multiple Myeloma
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
- Trial name
- MSC-CY (NCT02270307)
- Testing
- Cyclophosphamide, Mesenchymal stromal cells
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- National Research Center for Hematology, Russia
Leukemia, Lymphoma
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- ALHERT (NCT06409767)
- Testing
- Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.
- Where
- 10 sites in France
- Volunteers
- 2,224 people
- Sponsor
- University Hospital, Angers
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03733249
- Testing
- Rimiducid, rivogenlecleucel
- Where
- Italy
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals
Invasive Fungal Disease
Amphotericin B for Breakthrough Fungal Infections After Triazole Prophylaxis in Hematological Patients
The goal of this clinical trial is to learn if amphotericin B works to treat breakthrough invasive fungal disease (IFD) in patients with hematological diseases who have received azole-based prophylaxis.
- Trial name
- NCT07559032
- Testing
- Amphotericin B
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University People's Hospital
Hematologic Malignancies
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
This is a Phase II trial designed to evaluate the efficacy and toxicity of RIST, conditioned with fludarabine and busulfan, using G-CSF mobilized PBSC from an HLA-matched sibling or an unrelated volunteer donor.
- Trial name
- NCT00843947
- Testing
- Reduced Intensity Stem Cell Transplantation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Solid Tumor
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and…
- Trial name
- NCT06801002
- Testing
- JBZ-001
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jabez Bioscience, Inc
Sickle Cell Disease, Thalassemia
RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation.
- Conditions
- Sickle Cell Disease, Thalassemia, Hemolytic; Anemia, Hereditary, Due to Enzyme Disorder, Anemia Due to Membrane Defect
- Trial name
- RADeep (NCT06213402)
- Testing
- Data collection from EHR.
- Where
- Spain
- Volunteers
- 32,564 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Neoplasms
Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
This clinical trial studies the best time to administer the influenza vaccine to patients with non-hematologic malignancies receiving chemotherapy.
- Trial name
- NCT01695733
- Testing
- trivalent influenza vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
IASO-782 in Autoimmune Hematological Diseases
This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases.
- Trial name
- NCT06534021
- Testing
- IASO-782 injection
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai IASO Biotechnology Co., Ltd
Hematological Malignancy, Bone Marrow Failure Syndrome
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant…
- Trial name
- NCT00897260
- Testing
- Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma
Study of MLN8237 in Participants With Advanced Hematological Malignancies
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma
- Trial name
- NCT00697346
- Testing
- Alisertib
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Millennium Pharmaceuticals, Inc.